#1 Clinical Trials Search in Europe

Study of Baricitinib in Children Aged 1 to 17 Hospitalized with COVID-19

1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called Baricitinib in children who are hospitalized with COVID-19. COVID-19, also known as the coronavirus infection, is a disease caused by a virus that can lead to respiratory problems and other health issues. The medication being tested, Baricitinib, is provided in the form of an oral suspension, which means it is a liquid that is taken by mouth.

The purpose of this study is to understand how Baricitinib behaves in the body of pediatric patients, which includes children from 1 year to less than 18 years old. The study will look at how the medication is absorbed, distributed, and eliminated by the body. This information is important to ensure the safety and effectiveness of the treatment in young patients who are receiving oxygen therapy due to their COVID-19 infection.

During the study, participants will receive Baricitinib for a period of up to 14 days. Researchers will monitor the children closely to gather information about the medication’s safety and how it moves through the body. This will help determine the best way to use Baricitinib in treating children with COVID-19 in the future.

1 joining the study

Upon joining the study, the participant must be hospitalized with a confirmed COVID-19 infection and require oxygen therapy.

2 medication administration

The participant will receive Baricitinib, which is an oral suspension. This medication is taken by mouth.

The dosage and frequency of Baricitinib will be determined by the medical team based on the participant’s specific needs and condition.

3 monitoring and assessments

Throughout the study, the participant’s response to Baricitinib will be closely monitored. This includes measuring the concentration of the medication in the blood over time to understand how the body processes it.

The primary focus is on the pharmacokinetics, which involves studying the area under the concentration curve (AUC) and the maximum concentration (Cmax) of Baricitinib.

4 completion of the study

The study is estimated to conclude by December 31, 2024. The participant will continue to be monitored until the end of the study period to ensure safety and gather necessary data.

Who Can Join the Study?

  • Participants must be hospitalized with a coronavirus (COVID-19) infection. This means they need to be staying in a hospital because of the virus.
  • Participants must need oxygen therapy. This means they require extra oxygen to help them breathe better.
  • Participants must be at least 2 years old. This means they need to be 2 years of age or older.
  • Both female and male participants are eligible. This means the study is open to all genders.
  • The study includes people who might be considered vulnerable. This means it includes individuals who might need extra care or protection.

Who Cannot Join the Study?

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario De Navarra Pamplona Spain
Hospital Clinico San Carlos Madrid Spain

Other Sites

Site Name City Country Status
Centre Hospitalier Regional De La Citadelle Liege Belgium
Hospital Universitario 12 De Octubre Madrid Spain
Hospital Universitario Araba Vitoria Spain
Fobgfhytz Ppvs Lr Iycncvbtxkupf Bknmsuion Dqt Hsyhatuf Uuhlqmrghcuic Lf Ppb Madrid Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
21.12.2021
Spain Spain
Not recruiting
21.12.2021

Trial locations

Investigated drugs:

Baricitinib is a medication being studied for its effects in children with COVID-19. It is used to help reduce inflammation and manage the immune response in patients. In this trial, researchers are looking at how the body processes this medication in children who are hospitalized with COVID-19.

Investigated diseases:

COVID-19 – COVID-19 is a respiratory illness caused by the coronavirus SARS-CoV-2. It primarily spreads through respiratory droplets when an infected person coughs, sneezes, or talks. The disease can range from mild symptoms like fever, cough, and fatigue to more severe respiratory issues. In some cases, it can lead to complications such as pneumonia or acute respiratory distress syndrome. The progression of the disease varies widely among individuals, with some recovering quickly and others experiencing prolonged symptoms. The virus can also affect other organs, leading to a variety of symptoms beyond the respiratory system.

Trial ID:
2024-516824-32-00
Protocol code:
I4V-MC-KHAB
NCT ID:
NCT05074420
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

    Recruiting

    1 1
    Investigated diseases:
    Bulgaria Finland France Germany Italy Poland +2

  • Study of Remdesivir to Prevent Severe COVID-19 in Kidney Transplant Recipients with No or Mild Symptoms

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain